dsm-firmenich Q3 2025 Trading Update
On October 30, 2025, dsm-firmenich shared its trading update for the third quarter of 2025, highlighting promising growth indicators and strategic advancements. Dimitri de Vreeze, CEO, expressed confidence in the company's ongoing commitments, stating, "Our focus on core markets in nutrition, health, and beauty continues to drive our results. This reflects our ability to adapt and innovate in a rapidly changing landscape."
Q3 2025 Highlights
This quarter marked a solid trajectory with strong growth and an improved Adjusted EBITDA on a comparable basis. The strategic plan for 2025 is firmly on track, with significant progress in various business units.
Financial Overview
During this quarter, the company reported:
- Organic sales growth of 2%, a notable achievement given last year's high comparatives.
- Adjusted EBITDA of approximately €1.8 billion, up from €1.5 billion the previous year, showcasing a 19% increase.
- Adjusted EBITDA margin improved to 18.8%, compared to 15.9% in Q3 2024.
Strategic Developments
The company is also restructuring its Animal Nutrition & Health business, which is undergoing a divestment process. The management team is dedicated to finalizing this outcome by the end of the year.
Business Unit Reviews
dsm-firmenich's major business units have shown commendable performance:
- Perfumery & Beauty: Initiatives in Fine Fragrances and sustainable ingredients propelled sales, showcasing resilience against market fluctuations.
- Taste, Texture & Health: This segment supported the organic sales growth, achieving a strong 3% volume growth despite challenges in the broader market.
- Health, Nutrition & Care: Organic growth of 5%, with key contributions from Early Life Nutrition and Dietary Supplements, driving significant profitability.
- Animal Nutrition & Health: Continued solid performance, despite some setbacks in essential product lines.
Outlook for 2025
Looking ahead, dsm-firmenich anticipates a full-year Adjusted EBITDA of about €2.3 billion, influenced by foreign exchange dynamics and fluctuations in vitamin pricing related to the Animal Nutrition & Health sector. The team forecasts a significant €300 million increase in Adjusted EBITDA compared to 2024, fueled by organic growth and synergistic effects from recent mergers.
Share Buyback Program
In a bid to manage issued capital effectively, dsm-firmenich initiated a €1 billion share repurchase program, with approximately 85% already executed as of the latest update.
Frequently Asked Questions
What were dsm-firmenich's key highlights in Q3 2025?
The company reported a solid 2% organic sales growth, with Adjusted EBITDA up to €1.8 billion, reflecting improved margins.
How is dsm-firmenich progressing on its strategic plan?
dsm-firmenich is making significant strides in its strategic goals, including the ongoing divestment of its Animal Nutrition & Health business.
What impact did currency fluctuations have on dsm-firmenich's outlook?
Unfavorable foreign exchange impacts have been projected at approximately €90 million for the year, affecting financial forecasts.
Which business units showed notable growth during this quarter?
Perfumery & Beauty and Health, Nutrition & Care were among the high performers, driving overall growth for the company.
What is the expected Adjusted EBITDA for dsm-firmenich for the full year?
The company anticipates reaching around €2.3 billion in Adjusted EBITDA for the current fiscal year, bolstered by organic growth and synergy realization.
